Of note, in studies evaluating anti-CD30 CAR-T from in vitro cells to in vivo mouse models, third-generation CAR-T containing two costimulatory domains (CD28 and 4-1BB) demonstrated superior anti-tumor activity and tumor honing ability compared with second-generation CAR-T containing only one costimulatory domain (CD28). Here, CD28 is linked to neoplasm.